论文部分内容阅读
目的 评价三氧化二砷 (As2 O3)治疗原发性肝胆癌的疗效和不良反应。方法 中晚期原发性肝胆癌共 33例 ,其中肝癌 2 9例 ,胆囊癌 4例。单药As2 O3 注射液 15mg ,静脉滴注 ,1次 /d ,连用14～ 2 1d为一周期 ,间歇 2周重复。结果 总缓解率 15 .2 % ,其中原发性肝癌PR 4例 ,NC 2 1例 ,PD 4例。缓解率 13 8% ;胆囊癌CR 1例 ,NC 2例 ,PD 1例。主要不良反应为轻度的骨髓抑制和肝功能损害。结论 As2 O3 治疗原发性肝胆癌有较好疗效 ,不良反应少 ,值得进一步深入研究。
Objective To evaluate the efficacy and adverse reactions of arsenic trioxide (As2O3) in the treatment of primary hepatobiliary cancer. Methods A total of 33 patients with advanced hepatic and gallbladder cancer were included in the study, including 29 cases of hepatocellular carcinoma and 4 cases of gallbladder carcinoma. Single-agent As2O3 injection 15mg, intravenous drip, 1 time / d, combined with 14 to 21d as a cycle, repeated intermittently 2 weeks. Results The total remission rate was 15.2%, including 4 cases of primary liver cancer PR, 2 cases of NC, and 4 cases of PD. The remission rate was 13%; there was 1 case of gallbladder carcinoma CR, 2 cases of NC, and 1 case of PD. The main adverse reactions were mild myelosuppression and liver damage. Conclusion As2O3 is effective in the treatment of primary hepatobiliary cancer with few adverse reactions. It is worth further study.